Jeremy Green
CIK 1650527 · last filed 2026-06-15
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$389.57M
Companies
27
Total Filings
118
Lifetime Open-Market Net
$526.02M
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| FATE | Director | 12,884,277 | $2.37 | $30.54M | $210.71M | 21 | 2026-06-15 |
| STTK | Director | 5,615,489 | $6.71 | $37.68M | $119.34M | 10 | 2025-08-26 |
| IGM Biosciences, Inc. (IGMS) Delisted | Director | 0 | $1.27 | $0 | $12.90M | 31 | 2025-08-15 |
| ADCT | 10%+ Owner | 28,762,443 | $1.09 | $31.35M | $8.41M | 4 | 2024-12-13 |
| Augmedix, Inc. (AUGX) Delisted | Director | 16,421,788 | $2.35 | $38.59M | $13.00M | 8 | 2024-06-18 |
| ABSI | Director | 8,262,136 | $6.85 | $56.60M | $62.00M | 4 | 2024-06-14 |
| Science 37 Holdings, Inc. (SNCE) Delisted | Director | 0 | $5.75 | $0 | $0 | 6 | 2024-03-13 |
| MedAvail Holdings, Inc. (MDVL) Delisted | Director | 1,074,046 | $1.80 | $1.93M | $0 | 2 | 2022-07-06 |
| Invivyd, Inc. (ADGI) Delisted | 10%+ Owner | 1,920,960 | $4.64 | $8.91M | $49.98M | 1 | 2021-08-12 |
| Verve Therapeutics, Inc. (VERV) Delisted | 10%+ Owner | 1,936,530 | $11.13 | $21.55M | $39.90M | 1 | 2021-06-23 |
| APRE | 10%+ Owner | 88,436 | $0.64 | $56.6K | -$5.58M | 1 | 2021-02-16 |
| KYMR | 10%+ Owner | 1,630,660 | $104.91 | $171.07M | $0 | 1 | 2020-08-25 |
| Kalaris Therapeutics, Inc. (ALVR) Delisted | 10%+ Owner | 35,799 | $9.81 | $351.2K | $0 | 1 | 2020-08-05 |
| ANNX | 10%+ Owner | 1,596,222 | $4.87 | $7.77M | $0 | 1 | 2020-07-30 |
| Repare Therapeutics Inc. (RPTX) Delisted | 10%+ Owner | 1,586,174 | $2.65 | $4.20M | $0 | 1 | 2020-06-25 |
| Neurogene Inc. (NLTX) Delisted | 10%+ Owner | 1,002,986 | $13.96 | $14.00M | $3.58M | 1 | 2020-04-06 |
| BEAM | 10%+ Owner | 1,161,458 | $26.21 | $30.45M | $0 | 1 | 2020-02-11 |
| Akero Therapeutics, Inc. (AKRO) Delisted | 10%+ Owner | 743,802 | $54.65 | $40.65M | $0 | 1 | 2019-06-24 |
| Atreca, Inc. (BCEL) Delisted | 10%+ Owner | 715,306 | $0.15 | $107.3K | $0 | 1 | 2019-06-24 |
| STOK | 10%+ Owner | 671,808 | $29.73 | $19.97M | $0 | 1 | 2019-06-24 |
| ALDER BIOPHARMACEUTICALS INC (ALDR) Delisted | Director | 8,244,896 | — | — | $0 | 3 | 2019-05-24 |
| TCR2 THERAPEUTICS INC. (TCRR) Delisted | 10%+ Owner | 807,256 | $1.48 | $1.19M | $0 | 1 | 2019-02-21 |
| VAPOTHERM INC (VAPO) Delisted | 10%+ Owner | 102,085 | $2.17 | $221.5K | $0 | 1 | 2018-11-16 |
| REPL | 10%+ Owner | 779,655 | $5.24 | $4.09M | $0 | 1 | 2018-07-25 |
| Allakos Inc. (ALLK) Delisted | 10%+ Owner | 1,009,090 | $0.33 | $332.1K | $0 | 1 | 2018-07-24 |
| Syros Pharmaceuticals, Inc. (SYRS) Delisted | 10%+ Owner | 8,476 | $0.00 | $3 | $10.82M | 1 | 2016-07-07 |
| AMICUS THERAPEUTICS, INC. (FOLD) Delisted | 10%+ Owner | 12,956,446 | $14.49 | $187.74M | $954.7K | 1 | 2016-06-13 |
Recent Filings · Page 10 of 12
118 filingsInsider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2020-04-03 | IGM Biosciences, Inc. (IGMS) Delisted | Grant (A) | +356 | $0 | EDGAR |
| 2020-02-11 | BEAM | Conv (C) | +2,322,916 | $0 | EDGAR |
| 2019-10-24 | — | Mixed | −16,489,792 | $0 | |
| 2019-09-19 | IGM Biosciences, Inc. (IGMS) Delisted | Grant (A) | — | $0 | EDGAR |
| 2019-09-17 | FATE | Buy (P) | +1,714,286 | $30.00M | EDGAR |
| 2019-08-02 | FATE | Mixed | — | $0 | EDGAR |
| 2019-06-24 | Akero Therapeutics, Inc. (AKRO) Delisted | Conv (C) | +1,487,604 | $0 | EDGAR |
| 2019-06-24 | Atreca, Inc. (BCEL) Delisted | Conv (C) | +1,430,612 | $0 | EDGAR |
| 2019-06-24 | STOK | Conv (C) | +1,343,616 | $0 | EDGAR |
| 2019-05-24 | ALDER BIOPHARMACEUTICALS INC (ALDR) Delisted | Grant (A) | — | $0 | EDGAR |
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.